Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Keryx Has Cash For Three Years After $15M Private Placement

Nov. 19, 2003

By Aaron Lorenzo

Keryx Has Cash For Three Years After $15M Private Placement

Nov. 19, 2003

By Aaron Lorenzo

Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review

Nov. 18, 2003

By Aaron Lorenzo

MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi

Nov. 18, 2003

By Aaron Lorenzo

Amgen Reports Phase III Data On Cinacalcet, Gets Priority Review

Nov. 18, 2003

By Aaron Lorenzo

MGI In-Licenses Further Rights To Approved Cancer Drug Aloxi

Nov. 18, 2003

By Aaron Lorenzo

YM Licenses European Rights To Cancer Drug In $30M Deal

Nov. 13, 2003

By Aaron Lorenzo

YM Licenses European Rights To Cancer Drug In $30M Deal

Nov. 13, 2003

By Aaron Lorenzo

Aderis Drug Slows Ventricular Rate In Atrial Fibrillation Study

Nov. 12, 2003

By Aaron Lorenzo

Aradigm Adds To Cash Position With $13.5M Private Placement

Nov. 12, 2003

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...